The Safety of Anti-viral Therapy in Preventing HBV MTCT in Pregnant Women After Discontinuation

PHASE4CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

June 1, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Telbivudine 600mg

Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg daily between gestational weeks 24 and 28.

DRUG

Tenofovir disoproxil fumarate 300mg

Pregnant mothers who opted for antiviral therapy would start on oral TDF 300 mg daily between gestational weeks 24 and 28.

All Listed Sponsors
lead

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

NCT03468907 - The Safety of Anti-viral Therapy in Preventing HBV MTCT in Pregnant Women After Discontinuation | Biotech Hunter | Biotech Hunter